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ABSTRACT 
Purpose: α1-blockers improve voiding symptoms by reducing prostatic and urethral 
smooth muscle tone. However, the mechanism underlying improvements in storage 
symptoms is not known. Topical application of prostaglandin (PG) E2 to the rat lower 
urinary tract stimulates the micturition reflex (MR). Using an animal model, we 
investigated whether the α1-blocker tamsulosin acts on C-fiber afferent activity, and if 
so the location of this effect. 
Materials and Methods: To induce desensitization of C-fiber afferent activity 
resiniferatoxin (0.3 mg/kg, RTX) was subcutaneously injected in female 
Sprague-Dawley rats 2 days prior to experiments. Simultaneous recordings of urethral 
pressure and rhythmic bladder pressure were made under urethane anesthesia. PGE2 
(0.4 mg/ml) was continuously administered intravesically or intraurethrally to rats 
pretreated with RTX (RTX rats) or rats without pretreatment (non-RTX rats). We 
investigated the effects on MR of intravenous (2.2x10-1 – 2.2x103 nM/kg) or intrathecal 
(0.001 – 0.1 nmol) administration of tamsulosin.  
Results: Bladder contraction interval (BCI) was markedly reduced after intravesical or 
intraurethral administration of PGE2 in non-RTX rats, but was unchanged in RTX rats. 
This effect was antagonized by an EP1 receptor antagonist (ONO-8711). Intravenous 
administration of tamsulosin significantly increased BCI in non-RTX rats receiving 
intraurethral PGE2, but had no effect on non-RTX rats receiving intravesical PGE2. 
Intrathecal administration of tamsulosin produced a slight and insignificant increase in 
BCI in non-RTX rats receiving intraurethral PGE2. 
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Conclusion: These results suggest that PGE2 enhances MR through C-fiber afference 
and that tamsulosin had an inhibitory effect on the C-fiber urethral afferent nerves, 
thereby improving bladder storage function. 
 
INTRODUCTION 
   Benign prostatic hyperplasia (BPH) is an age-related increase in the volume of the 
prostate, which leads to voiding and storage dysfunction caused by bladder outlet 
obstruction (BOO). The functional importance of α1-adrenoceptors (α1-ARs) in the 
sympathetic nerve terminals of the prostate has been indicated, and it has been shown 
that dynamic obstruction is mediated by α1-AR stimulation. Medical treatment of 
voiding, storage or both symptoms suggestive of BOO is now the initial choice of 
therapy, and α1-AR blockers remain the most widely used pharmacological agents 
aimed at the dynamic component of prostatic obstruction.1  
Recent attention has focused on the classification of neural supply to the 
bladder and prostate. Presently, α1-ARs are generally subdivided into α1A-, α1B-, and 
α1D-AR subtypes.2 The α1a-AR subtype predominates in the prostatic stroma at the 
mRNA and protein level, and is responsible for the dynamic component of obstruction 
and related voiding symptoms.3 The α1d-AR subtype is expressed in the detrusor, 
prostate, peripheral ganglia, and spinal cord in humans and rats.4-7 Recently, a number 
of experimental findings have indicated the involvement of the α1D-AR subtype in the 
storage symptoms.5,8 Because α1- AR blockers act during the storage phase to allow an 
increase in bladder capacity and a decrease in urgency, it is thought that they exert an 
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inhibitory effect on afferent nerves. However, the mechanism by which these blockers 
improve storage symptoms remains unknown. 
   Prostanoids, in particular prostaglandin (PG) E2, have been implicated as 
endogenous modulators of bladder function under both physiological and 
pathophysiological conditions.9 PG synthesis occurs locally in the bladder muscle and 
mucosa, and is initiated by various physiological stimuli such as detrusor muscle stretch 
and nerve stimulation, as well as by injury and mediators of inflammation. Several 
investigators have shown that PGE2 can contract isolated human as well as animal 
detrusor muscle.9 This effect is unlikely to contribute to voiding contraction even if 
PGE2 does facilitate the action of the endogenous efferent neurotransmitter 
acetylcholine.10 In vivo, endogenous prostanoids may enhance voiding efficiency 
through a direct or indirect effect on sensory nerves.11 Topical application of PGE2 to 
the bladder stimulates the micturition reflex (MR) in humans and rats.12,13 Increases in 
COX-2 expression and PGs in the bladder wall have been shown to play an important 
role in the development of detrusor overactivity caused by BOO.14,15 To our knowledge, 
however, the influence of intraurethral PGE2 on MR has not been investigated.  
   In the present study, we investigated whether tamsulosin,16 an α 1A-and α 1D-AR 
blocker, acts on C-fiber afferents by comparing its effect on induced detrusor 
overactivity in C-fiber-desensitized and C-fiber normal rats. We also studied the effect 
of intravenous (iv) and intrathecal (it) administration of tamsulosin on the detrusor 
overactivity induced by intravesicular or intraurethral PGE2. 
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MATERIALS AND METHODS 
   A total of fifty-two female Sprague-Dawley rats weighing 225-268 g (mean = 252 g) 
were used. They were housed at a constant temperature (23 ± 2ºC) and humidity 
(50-60%) under a regular 12-h light/dark cycle (lights on 7:00 AM - 7:00 PM). Tap 
water and standard rat chow were freely available. All experiments were performed in 
strict accordance with the guidelines of the Institutional Animal Care and Use 
Committee of the University of Fukui.  
Simultaneous recordings of urethral and rhythmic bladder pressure 
   To induce desensitization of C-fiber afferent activity, we subcutaneously injected 
resiniferatoxin (0.3 mg/kg, RTX) 2 days prior to experiments. All surgical and 
urodynamic procedures were performed under urethane anesthesia (1.0 g/kg). The 
bladder and proximal urethra were exposed through a midline abdominal incision. 
Urethral activity, measured as urethral perfusion pressure, was monitored using a 
polyethylene catheter (size 3; i.d. 0.5 mm, o.d. 1.0 mm; Kunii Co. Ltd., Tokyo, Japan) 
with the tip embedded in a cone-shaped plug that was introduced transvesically through 
an incision in the bladder dome and then seated securely in the bladder neck.17 The 
cone-shaped plug was fashioned from Eppendorf pipette tip. The catheter end was then 
exteriorized at the external urethral meatus. To monitor intravesicular pressure, the 
bladder end of a catheter (size 4; i.d. 0.8 mm, o.d. 1.3 mm; Kunii Co. Ltd., Tokyo, 
Japan) was heated to create a collar and passed through the same incision of the bladder 
dome. This arrangement permitted the functional separation of bladder and urethral 
activity without the risk of surgical damage to the vesicourethral innervation associated 
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with a urethral ligation or total urethrotomy. The bladder catheter was connected to a 
pump (TE-311; Terumo Co. Ltd., Tokyo, Japan) for infusion of physiological saline and 
to a pressure transducer (TP-200T; Nihon-Kohden Co., Ltd., Tokyo, Japan) by means of 
a polyethylene T-tube. The urethral catheter was connected to a pump for continuous 
saline infusion (0.075 ml/min) and to a pressure transducer by means of a polyethylene 
T-tube.  
Experimental protocol 
   After a 30-min postsurgical stabilization period, pressure recordings from the 
bladder and urethra were started. The bladder was filled with saline at a rate of 0.1 
ml/min to induce the micturition reflex, which was evident by rhythmic, 
large-amplitude bladder contractions. Bladder filling was then discontinued and 
isovolumetric pressure was recorded. The urethra was continuously infused with saline 
(0.075 ml/min). Thus, isovolumetric bladder and urethral perfusion pressure were 
recorded independently and simultaneously. The values of the three parameters (bladder 
contraction interval, BCI; bladder contraction pressure, BCP; and bladder contraction 
duration, BCD) were obtained from the micturition reflex measurements (Fig. 1). 
Drug administration 
   PGE2 (0.4 mg/ml) dissolved in 0.1 M phosphate buffer (pH 7.4) was continuously 
administered intravesically or intraurethrally to rats pretreated with RTX (RTX rats) or 
rats without pretreatment (non-RTX rats). To confirm whether the effect of PGE2 on 
MR was mediated by the EP1 receptor, ONO-8711 
{6-[(2S,3S)-3-(4-chloro-2-methylphenylsulfonylaminomethyl)-bicyclo[2.2.2]octan-2-yl
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]-5Z-hexenoic acid}, a selective EP1 antagonist chemically synthesized at Ono 
Pharmaceutical Co., Ltd. (Osaka, Japan), was given by intravenous administration. The 
effect of tamsulosin (Astellas Pharma Inc., Tokyo, Japan) on intravesical or intraurethral 
PGE2-stimulated MR was investigated at iv doses of 2.2 x 10-1 – 2.2 x 103 nM/kg and it 
doses of 0.001 – 0.1 nmol.  
Data analysis 
   Data are expressed as the mean ± standard error of the mean (SEM). Statistical 
comparisons were performed using one- or two-way repeated measures analysis of 
variance (ANOVA), with subsequent individual comparisons conducted using Fisher’s 
PLSD test. The two groups were compared using Mann Whitney’s U-test or Wilcoxon 
signed-ranks test. A level of p < 0.05 was considered statistically significant. 
 
RESULTS 
Effects of PGE2 on micturition reflex 
   BCI was markedly reduced after intravesical or intraurethral administration of PGE2 
in non-RTX rats (Figs. 1, 2, 3), but was unchanged in RTX rats. Intravesical and 
intraurethral administration of PGE2 decreased BCI by 40.9% and 23.1%, respectively, 
with these ratios expressed as 0% in Fig. 3 as baseline ratios for the next experiment. 
These effects were antagonized by the EP1 receptor antagonist ONO-8711 (1 mg/kg, iv). 
PGE2 by intravesical administration gradually increased voiding threshold pressure (Fig. 
1), whereas that by intraurethral administration had no effect (Fig. 2). 
Effects of tamsulosin on PGE2-stimulated micturition reflex 
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   Intravenous administration of tamsulosin significantly increased BCI in rats 
receiving intraurethral PGE2 (p <0.05), but had no particular effect on those receiving 
intravesical PGE2 (Figs. 3, 4, 5). The percentage increases in BCI in rats receiving 
intraurethral and intravesical PGE2 at 2.2 x 103 nM/kg tamsulosin were 89.4% and 
18.9%, respectively. The high dose of tamsulosin did not increase BCI in rats receiving 
intravesical PGE2, whereas ONO-8711 (1 mg/kg iv) completely reversed the influence 
of PGE2 on BCI (Fig. 5). Further, in rats not receiving PGE2, tamsulosin showed no 
significant effect on BCI (Fig. 3), and had no effect on BCI in RTX rats. The high dose 
of tamsulosin (2.2 x 103 nM/kg) decreased BCP in rats receiving intraurethral or 
intravesical PGE2 and in rats not receiving PGE2 by 26.1%, 8.2%, and 47.5%, 
respectively (Fig. 6). Further, tamsulosin by intravenous administration had no effect on 
BCD in any treatment group (Fig. 7), although intrathecal administration produced a 
slight and insignificant increase in BCI in rats receiving intraurethral PGE2. 
 
DISCUSSION 
   Our findings indicate that PGE2 produces an excitatory effect on MR by stimulation 
of C-fiber afferent nerves via the EP1 receptor. This effect of PGE2 was seen on 
application to either the bladder or the urethra. Tamsulosin by intravenous 
administration had an inhibitory effect on this agonistic effect on MR of intraurethral 
but not intravesical PGE2 and did not produce a decrease in BCP at low doses. 
Tamsulosin by intrathecal administration, in contrast, had only a slight and insignificant 
inhibitory effect on intraurethral PGE2-stimulated MR. These results support the 
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hypothesis that this α1-AR blocker improves detrusor overactivity by inhibiting C-fiber 
afferent activity in the urethra rather than in the spine, and this effect does not depend 
on the inhibition of C-fiber afferent activity in the spine. 
   Studies in rats and humans have demonstrated that intravesical administration of 
PGE2 results in detrusor overactivity.12,13 PGE2 produces its endogenous activity via the 
EP receptor family of G protein-coupled receptors, of which four subtypes have been 
identified to date. Using EP1 receptor knockout mice, Schröder demonstrated that the 
EP1 receptor was not essential for normal micturition but did play a role in the 
development of detrusor overactivity caused by PGE2 and BOO.15 In the present study, 
continuous intravesical administration of PGE2 caused a significant decrease in BCI in 
non-RTX rats, whereas ONO-8711 antagonised this effect. These findings indicate that 
these effects of PGE2 are attributable to the stimulation of EP1 receptors. Further, RTX 
rats did not respond to intravesical PGE2, leading us to hypothesize that PGE2 produces 
its excitatory influence on MR by stimulating C-fiber afferent nerves via the EP1 
receptor. 
   In the present study, the excitatory effects on MR produced by intravesical 
administration of PGE2 were also seen in non-RTX rats receiving intraurethral 
administration, but not in RTX-rats. The mechanism of this overactivity is unknown, but 
may be inititiated by a PGE2–mediated increase in urethral afferent activity. It has been 
suggested that detrusor overactivity caused by BOO may be initiated from the bladder 
outlet region rather than from the bladder itself.18 In cats, urethral perfusion triggered 
spontaneous bladder contraction of such intensity and frequency that bladder filling was 
 9
not possible.19 Pharmacological activation of urethral afferent nerves by intraurethral 
capsaicin elicited a biphasic change in MR,17 initially decreasing BCI within minutes, 
followed 15 to 30 min later by complete MR blockage. Immunohistochemical data have 
indicated the presence of capsaicin-sensitive primary afferent fibers in the rat proximal 
urethra.20 Considering these findings and the antagonistic effect of ONO-8711 on 
PGE2-stimulated MR, urethral C-fiber afferent activity may be a trigger to the induction 
of detrusor overactivity via the EP1 receptor in rats. 
   A recent study reported that α1d-AR mRNA is present in the human detrusor, that 
the ratio of α1d-AR mRNA is higher than that of α1a-AR mRNA, and that the α1D-AR 
subtype is closely related to the storage symptoms encountered in patients with BPH.4 
The ratio of α1d-AR subtype to all α1-AR subtype mRNAs has been reported to be 
higher in the obstructed rat bladder.5 α1- AR blockers with significant affinity for the 
α1D-AR subtype are therefore thought able to improve storage symptoms related to 
BOO. Nomiya et al. found that mRNAs of the α1a-, α1b-, and α1d-AR subtypes are 
expressed at low levels in the obstructed human bladder, whereas β3−AR mRNA is 
highly expressed.7 They suggested that bladder α1-ARs are not likely to be responsible 
for the detrusor overactivity and storage symptoms in patients with BPH.  
In the present study, tamsulosin had an inhibitory effect on intraurethral 
PGE2-stimulated MR, but not on intravesical PGE2-stimulated MR. This result lead us 
to hypothesize that tamsulosin exerts an inhibitory effect on C-fiber afferent nerves in 
the urethra. Tamsulosin is a combined α1A and α1D-AR antagonist which exerts a 
relaxant effect on urethral rather than bladder smooth muscle. The α1-AR subtype 
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predominates in prostatic stroma at the mRNA and protein level, and is responsible for 
the dynamic component of obstruction.3 Taken together, these findings suggest that 
tamsulosin exerts an inhibitory effect on C-fiber urethral afferent nerves by decreasing 
urethral tonus, and thereby improving of storage symptoms. However, using urethane 
treated animal increases the risk that effects of α-AR blockers in the spinal cord will be 
masked by the urethane. In order to really confirm C-fiber urethral afferent nerves, it is 
ideally necessary to record the activity from identified C-fibers. Further research on the 
underlying mechanisms of the interaction between α1-AR and C-fiber afferent activity 
in the urethra may lead to new therapeutic modalities targeted at detrusor overactivity. 
 
CONCLUSION 
   In vivo animal study reveals that exogenous PGE2 enhances MR through effects on 
C-fiber efferent nerves in both the bladder and urethra. Tamsulosin has an inhibitory 
effect on C-fiber urethral afferent nerves, thereby improving bladder storage function. 
These findings are likely to be applicable to the human subject and to explain the 
mechanism that α1-AR blockers improve storage symptoms. 
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FIGURE LEGENDS 
Figure 1. Simultaneous recordings of isovolumetric bladder and urethral perfusion 
pressure before (A) and 10 min after (B) intravesical administration of prostaglandin 
(PG)E2. Intravesical PGE2 facilitated rhythmic bladder contraction and gradually 
increased voiding threshold pressure. BCI: Bladder Contraction Interval, BCP: Bladder 
Contraction Pressure, BCD Bladder Contraction Duration. 
Figure 2. Simultaneous recordings of isovolumetric bladder and urethral perfusion 
pressure before (A) and 10 min after (B) continuous intraurethral administration of 
PGE2. Intraurethral PGE2 facilitated rhythmic bladder contraction but did not increase 
voiding threshold pressure. 
Figure 3. Effects of intravenous tamsulosin (2.2 x 10-1 – 2.2 x 103 nM/kg) on bladder 
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contraction interval (BCI) in urethane-anesthetized rats. Intraurethral and intravesical 
administration of PGE2 significantly reduced BCI (circles and triangles, respectively). 
BCI values after intravesical or intraurethral administration of PGE2 are expressed as 
0%. Increases in BCI were recognized at increasing doses of tamsulosin in rats 
receiving intraurethral PGE2, whereas no change was seen in rats receiving intravesical 
PGE2. Single asterisk indicates p <0.05 vs rats receiving intravesical PGE2. No change 
in BCI was seen with increasing doses of tamsulosin in rats not receiving PGE2 
(squares). 
Figure 4. Effect of intravenous tamsulosin (2.2 nM/kg) on simultaneous recordings of 
isovolumetric bladder and urethral perfusion pressure bladder contraction interval in 
urethane-anesthetized rats receiving intraurethral administration of PGE2. Note that 
tamsulosin increased bladder contraction interval. 
Figure 5. Effect of a high dose (2.2 x 103 nM/kg) of intravenous tamsulosin on 
simultaneous recordings of isovolumetric bladder and urethral perfusion pressure in 
urethane-anesthetized rats receiving intravesical administration of PGE2 (A). Note that 
tamsulosin slightly increased bladder contraction interval (BCI). Intravenous 
administration of ONO-8711 increased BCI at a dose of 1 mg/kg (B). 
Figure 6. Effect of intravenous tamsulosin (2.2 x 10-1 – 2.2 x 103 nM/kg) on bladder 
contraction pressure (BCP) in urethane-anesthetized rats. Intraurethral and intravesical 
administration of PGE2 significantly reduced BCP (circles and triangles, respectively). 
BCP values after intravesical or intraurethral administration of PGE2 was expressed as 
0%. In rats not receiving PGE2 (squares) BCP values before administration of 
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tamsulosin are expressed as 0%. Decreases in BCP were seen with a high dose (2.2 x 
103 nM/kg) of tamsulosin in rats receiving intraurethral PGE2 and in rats not receiving 
PGE2. Single asterisk indicates p <0.05 vs before administration of tamsulosin.  
Figure 7. Effect of intravenous tamsulosin (2.2 x 10-1 – 2.2 x 103 nM/kg) on bladder 
contraction duration (BCD) in urethane-anesthetized rats. Intraurethral and intravesical 
administration of PGE2 significantly reduced BCD (circles and triangles, respectively). 
BCD values after intravesical or intraurethral administration of PGE2 are expressed as 
0%. BCD values before administration of tamsulosin are expressed as 0% in rats not 
receiving PGE2 (squares). No changes were found in the three treatment groups. 
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